Elicio Therapeutics, Inc. (ELTX): Cash & Equivalents
$18.56M
As of 2025-12-31
$23.48M
As of 2026-06-30
+44.5%
3-year compound annual growth
-11.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.56M | +5.4% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $17.62M | +36.6% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $12.89M | +109.5% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $6.16M | -93.1% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $88.76M | +156.5% | 2023-03-17, Balance as of period end |
| 2020-12-31 | $34.61M | n/a | 2022-03-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Elicio Therapeutics, Inc. (ELTX) | 2025-12-31 | $18.56M | +5.4% |
| BeyondSpring Inc. (BYSI) | 2025-12-31 | $7.79M | +166.5% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $5.63M | -58.2% |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $3.62M | +115.6% |
| Aptevo Therapeutics Inc. (APVO) | 2025-12-31 | $21.62M | +148.1% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $1.95M | -58.2% |
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | $3.62M | -71.4% |
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $8.70M | +129.3% |
| Rein Therapeutics, Inc. (RNTX) | 2025-12-31 | $3.21M | -75.0% |
Compare ELTX, BYSI, CASIF, INBP side by side · Screen every company in Pharmaceutical Preparations ↗